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Cancer treatment is increasingly based on the use of drugs
targeting speciﬁc genes or pathways. This is the result of years
of cancer research aiming at identifying suitable targets as
well as highly selective and eﬀective compounds. However,
strong single gene-single drug pharmacogenomics associa-
tions are rarely observed, and it is becoming clear that cancer
response or resistance to treatment underlies much more
complex mechanisms.
Understanding such mechanisms is key to developing
predictive biomarkers able to identify which patients are
likely to respond to a speciﬁc treatment. Unfortunately, in
most clinical scenarios, there is a lack of adequate predictive
biomarkers. As a consequence, a large proportion of patients
are either overtreated or receive ineﬀective treatments, chal-
lenging the eﬀective implementation of a precision medicine.
We set up this special issue with such a framework in
mind, seeking for original research papers and reviews giving
insights into the latest advances in the ﬁeld. The series
of included manuscripts clearly highlights how vast and
heterogeneous the deﬁnition of predictive biomarkers can
be. It could be measured in diﬀerent tissue types (e.g., tumour
or liquid biopsies) and could be any entity besides the stan-
dard clinicopathological parameters, ranging from genetic
mutations to epigenetic and metabolic changes.
P. Bossi et al. in “Are Fusion Transcripts in Relapsed/
Metastatic Head and Neck Cancer Patients Predictive of
Response to Anti-EGFR Therapies?” investigated the predic-
tive role of fusion transcripts in head and neck squamous cell
carcinoma treated with chemotherapy and cetuximab,
identifying the CD274-PDCD1LG2 fusion as enriched in
short-PFS patients and associated with worse survival
within this subgroup.
N. Bedini et al. in “Evaluation of Mediators Associated to
the Inﬂammatory Response in Prostate Cancer Patients
Undergoing Radiotherapy” explored the hypothesis that a
previous surgery may inﬂuence plasma level of inﬂammatory
molecules in prostate cancer patients, resulting in enhanced
radiosensitivity. The levels of six inﬂammation mediators
were measured in a cohort of prostate cancer patients under-
going radical radiotherapy, and CCL2 levels were found to be
signiﬁcantly higher in patients experiencing grade 2 toxicity.
There is a growing interest in developing noninvasive
approaches to monitor cancer progression and response to
treatment. M. Verduin et al. thoroughly describe the state-
of-art for glioblastoma in the review titled “Noninvasive
Glioblastoma Testing: Multimodal Approach to Monitoring
and Predicting Treatment Response.” In this review, the
authors discuss multiple approaches and their eﬀect on pre-
dicting and monitoring treatment response in glioblastoma.
This set of diagnostic approaches comprises advanced MRI
techniques, nuclear imaging, liquid biopsy, and new inte-
grated approaches including radiogenomics and radiomics.
Moving to breast cancer, a crucial aspect of this disease is
its extensive heterogeneity, deﬁnitely demonstrated at geno-
mics, transcriptomics, and proteomics level. V. Cappelletti
et al. in “Metabolic Footprints and Molecular Subtypes in
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Breast Cancer” clearly show that such heterogeneity is pres-
ent also at the metabolic level. After a brief overview of the
literature on molecular subtypes and an account of major
metabolic pathways in cancer, original metabolomics data
from a series of primary breast cancer patients are reported.
Intriguingly, the luminal B subgroup represents a tumour
type that preferentially relies on fatty acids for energy,
whereas HER2 and basal-like ones prevalently show alter-
ations in glucose/glutamine metabolism. This could enable
the development of new breast cancer subtype-speciﬁc
therapeutic strategies and associated biomarkers.
M. Aubele et al. in “The Predictive Value of PITX2 DNA
Methylation for High-Risk Breast Cancer Therapy: Current
Guidelines, Medical Needs, and Challenges” focused on the
triple-negative subtype of breast cancer that, together with
cases having more than three positive lymph nodes, consti-
tutes a high-risk group for which guidelines recommend
anthracycline-based chemotherapy as the standard of care.
However, only a proportion of patients beneﬁt from this
treatment and methylation of the PITX2 (paired-like home-
odomain transcription factor 2) gene might serve as a novel
predictive biomarker. This review speciﬁcally discusses the
future clinical application of PITX2 as a predictive biomarker
to personalize breast cancer management.
Finally, M. Di Modica et al. in “Predicting the Eﬃcacy of
HER2-Targeted Therapies: A Look at the Host” draw their
attention on another breast cancer subtype, HER2-positive
tumours, for which a targeted therapy is available, that is,
trastuzumab/Herceptin, a monoclonal antibody targeting
HER2. However, a proportion of patients do not respond
to this agent, whereas new drugs have proven to be eﬃca-
cious in clinical trials. Biomarker-based stratiﬁcation of the
HER2-positive subtype is therefore needed, and in this
review, the authors discuss in particular the role of the
immune system in shaping the response.
Overall, manuscripts in this issue highlighted how
extremely diﬀerent aspects of the tumour and of the host
can impact and determine response or resistance to treat-
ment. Future research eﬀorts should aim to a multidimen-
tional characterization of both the tumour and the host/
microenvironment and to the development of data integra-
tion strategies. This is probably the best way to capture the
complexity behind cancer response to treatment and develop
predictive biomarkers able to reach the high accuracy
required for their clinical implementation.
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